Overview of Metaflam

Property	Description
Active ingredient	Mefenamic Acid
Form	Oral capsule or tablet
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use	Acute pain, inflammation, and fever
Origin	Synthetic organic compound (Fenamate subclass)

What Type of Medicine is Metaflam?

Metaflam, when referring to the product containing the active ingredient Mefenamic Acid, is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Mefenamic Acid belongs specifically to the fenamate chemical subclass, structurally known as an anthranilic acid derivative, a synthetic organic substance supplied as a single-ingredient product for the oral route of administration. Unlike many other widely available NSAIDs, Mefenamic Acid is often designated as prescription-only (Rx) due to its pharmacological profile.

This classification signifies that the product is inherently designed to manage symptoms related to pain, inflammation, and fever. Structurally, the fenamate classification sets it apart from propionic acid derivatives like ibuprofen, establishing a specific pharmacological profile that is clinically recognized for managing acute pain and associated inflammation.

Composition and General Purpose

The therapeutic efficacy of Metaflam is derived entirely from its active component, Mefenamic Acid. The overall functional goal is to provide relief from acute mild-to-moderate discomfort, such as the pain associated with musculoskeletal injuries.

The general purpose is rooted in its ability to exert three key effects: analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing). Mefenamic Acid works by inhibiting the production of prostaglandins, which are chemical messengers that drive pain and inflammation. This targeted action makes the product suitable for conditions where these three symptoms are present and require prompt, short-term management.

What side effects are possible with Metaflam?

Metaflam (meloxicam) has an official safety profile that highlights several serious and common risks documented by government regulatory agencies.

Serious Systemic Risks (Boxed Warning)

The most critical safety information includes a Boxed Warning regarding the potential for serious, life-threatening, or fatal adverse events:

Cardiovascular Thrombotic Events: Use may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke. This risk may increase with the duration of use and in patients with pre-existing cardiovascular disease or risk factors. This medicine is strictly contraindicated for the treatment of peri-operative pain following coronary artery bypass graft (CABG) surgery.
Gastrointestinal (GI) Events: The drug increases the risk of serious GI adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. The risk is higher in the elderly and in those with a prior history of GI bleeding or ulcer disease.

Common and Less Common Adverse Reactions

Adverse reactions reported in clinical trials and organized by system-organ class include:

Gastrointestinal Disorders: The most common reactions often reported are dyspepsia (indigestion), diarrhea, and abdominal pain.
Nervous System Disorders: Headache and dizziness are commonly reported.
Skin and Immune System: Serious skin reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and severe allergic reactions (anaphylaxis) have been reported and require immediate discontinuation.

Restrictions and Population-Specific Safety

Safety data specifies that the risk of serious adverse cardiovascular and gastrointestinal events may be minimized by using the lowest effective dose for the shortest duration possible.

Pregnancy: Use is generally avoided from 30 weeks gestation onward due to the risk of premature closure of the fetal ductus arteriosus. Use between 20 and 30 weeks is also limited due to the potential for fetal renal dysfunction.
Contraindications: Metaflam is contraindicated in patients with a history of asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or other NSAIDs, in addition to the restrictions noted above.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented overdose manifestations and required emergency actions for Mefenamic Acid (Metaflam), based strictly on government regulatory labeling.

Documented Overdose Presentations

Overdose has been associated with effects on the Central Nervous System (CNS) and major organs. Officially documented manifestations include:

CNS Toxicity: Seizures (or Convulsions), Coma, Confusional state, Vertigo, and Hallucination.
Gastrointestinal Effects: Nausea, Vomiting, Epigastric pain, and Gastrointestinal bleeding.
Severe Outcomes: Acute renal failure and Fatalities have been reported following overdose.

Official Emergency Actions

Immediate medical attention is formally required for any suspected overdose. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, emergency services should be called immediately.

Action Area	Official Regulatory Documentation
Antidote	No specific antidote is available; treatment is symptomatic and supportive.
Decontamination	The stomach should be emptied by inducing emesis or gastric lavage followed by the administration of activated charcoal.
Monitoring	Vital functions should be monitored and supported, with observation required for at least 12 hours.

Children who have ingested more than 25 mg/kg should be given activated charcoal. The overall management strategy is centered on supportive care, as documented in official prescribing information.

Therapeutic Uses of Metaflam

What Metaflam Treats: Main Uses and Benefits

Metaflam (Mefenamic Acid) is commonly used across domains where additional symptomatic support is needed, especially when symptoms interfere with daily functioning. The medication is applied in scenarios where short-term symptomatic assistance is appropriate for acute, mild-to-moderate discomfort.

The medication is relevant in conditions characterized by periods of heightened symptoms, including managing discomfort related to mild-to-moderate pain, addressing primary dysmenorrhea (menstrual cramps), and easing fever. In conditions involving acute physical discomfort, the medication is relevant for managing symptom clusters that may become intense or disruptive, such as swelling, tenderness, and symptoms related to systemic imbalance.

Quick Fact: Relief for Pain and Cramping

Quick Fact: Relief for Pain and Cramping Metaflam is generally applied when symptoms become more noticeable, and may assist with supportive relief for acute discomfort arising from musculoskeletal injuries or the recurrent, cramping pain associated with the menstrual cycle.

Eligibility and Restrictions for Use

The eligibility profile for Metaflam (Mefenamic Acid) is defined by strict regulatory criteria established by health authorities. These criteria specify which population groups are permitted to use the medicine and which are subject to absolute prohibition or conditional restrictions.

Populations Allowed and Not Established

Eligibility Status	Official Regulatory Rule
Allowed Use	Adults and adolescents aged 14 years and older are eligible for labeled uses.
Use Not Established	Safety and efficacy have not been established for children younger than 14 years of age.

Absolute Contraindications

Use of Metaflam is contraindicated in patients with the following conditions:

Known hypersensitivity to aspirin or any other Nonsteroidal Anti-inflammatory Drug (NSAID).
Active gastrointestinal ulceration or chronic inflammation, or Inflammatory Bowel Disease (IBD).
Severe renal failure, severe hepatic failure, or severe heart failure.
Pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
The last trimester of pregnancy (ge 30 weeks gestation).

Conditional Use and Restrictions

Pregnancy (20–30 Weeks): Use is not recommended and should be avoided due to the potential risk of fetal renal dysfunction.
Elderly Patients: Use requires the lowest effective dose for the shortest duration possible due to an increased risk of serious adverse effects.
Lactation: Use is not recommended while breastfeeding.

What should I know about interactions with other medicines?

Official Interaction Profile

The documented interaction profile for Mefenamic Acid (Metaflam) is classified by regulatory authorities based on two main patterns: additive safety risks and altered drug exposure.

Contraindicated Combinations and Restrictions The medication is strictly restricted from use for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, should be avoided due to the officially documented increased risk of serious gastrointestinal events. Timing-based restrictions require that the medication not be taken for 8 to 12 days after Mifepristone administration.

Pharmacodynamic Interactions (Additive Risks) Mefenamic Acid co-administration can increase the risk of GI or non-GI bleeding when taken with oral anticoagulants (e.g., Warfarin), antiplatelet agents (e.g., low-dose Aspirin), Corticosteroids, or SSRIs. Additionally, it can reduce the blood pressure-lowering effect of Antihypertensives such as ACE Inhibitors, ARBs, and Diuretics.

Exposure-Altering Interactions Co-administration is officially noted to raise the plasma concentration of certain medicines by reducing their clearance, including Lithium and Methotrexate. The metabolism of Mefenamic Acid involves the CYP2C9 enzyme. Furthermore, Antacids containing Magnesium Hydroxide are documented to significantly increase the rate and extent of Mefenamic Acid absorption. Concomitant consumption of Alcohol may also increase the risk of gastrointestinal bleeding.

Population-Specific Notes The risk of developing severe renal impairment when combining with RAAS-targeting drugs is officially heightened in elderly or volume-depleted patients.

Mechanism of Action

How Metaflam Works

The drug's mechanism involves the modulation of the body's eicosanoid chemical signaling pathways, operating through two primary, interconnected steps.

Inhibition of Cyclooxygenase (COX) Enzymes

The drug functions as a non-selective competitive inhibitor on its biological targets: the Cyclooxygenase (COX-1 and COX-2) enzymes . The drug binds at the active site of these enzymes, which are responsible for initiating the conversion of arachidonic acid into chemical precursors. By binding at this site, the drug interferes with the enzyme's catalytic activity.

Modulation of Prostaglandin Synthesis

Inhibition of the COX enzymes directly results in a reduction in the synthesis and subsequent release of specific signaling molecules known as prostaglandins. The reduction in the concentration of these lipid mediators decreases the chemical signaling that influences local vascular permeability and the sensitivity of peripheral neurons. This molecular action results in an altered physiological state characterized by reduced mediator activity within the tissue and diminished afferent input.

Dosage and Administration Information

Instruction Map: How to use Metaflam (Mefenamic Acid)

This map outlines the standardized procedural instructions for the use of Mefenamic Acid.

Administration Scope

Feature	Guideline
Route of administration:	Oral administration only.
Dosing schedule:	Initial dose of 500 mg once, followed by a maintenance dose of 250 mg.
Timing in relation to meals (if applicable):	Should be taken with food or milk to help mitigate potential gastrointestinal upset.
Preparation requirements (if applicable):	The capsule or tablet should be swallowed whole with water.
Age-group administration rules:	Approved for patients 14 years of age and older. Use in older adults should adhere to the lowest effective dose for the shortest duration.
Missed-dose rules:	If a dose is missed, skip the missed dose and resume the regular schedule; do not double doses.
Special procedural conditions:	Treatment for primary dysmenorrhea must begin specifically at the onset of bleeding and associated pain.

Instruction Classifications (High-Level)

Classification	Pattern
Administration method type:	Oral
Frequency pattern:	Every 6 hours (q6h) as needed; Short-term course limitation.
Use-context constraints:	Duration of use for acute pain is limited to 7 days; duration for dysmenorrhea is limited to 2 to 3 days.

Resulting Procedural Structure

Step sequence:

Initiate treatment with the 500 mg initial dose for acute indications.
Follow the initial dose with the 250 mg maintenance dose.
Take the maintenance dose every six hours, with food or milk, until the condition-specific time limit is reached.

Connection to the overall use protocol

The instructions establish a precise, time-limited regimen for Mefenamic Acid use, mandating an oral route and a 500 mg loading dose before transitioning to a 250 mg maintenance dose. This protocol dictates a fixed frequency of every six hours and imposes a strict duration limit, which frames the medication as a short-course therapeutic tool managed by explicit time parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metaflam

Metaflam (Mefenamic Acid) was evaluated in clinical research primarily through controlled trials that examined its use for its studied short-term indications. This research helps contribute to the broader evidence landscape by describing how symptoms evolved in the observed populations under specific study conditions. Research describes the patterns observed when the product was studied for certain conditions.

Evidence for Use in Primary Dysmenorrhea

Research exploring whether Mefenamic Acid influences primary dysmenorrhea (menstrual cramping/pain) has largely centered on short-term Randomized Controlled Trials (RCTs) and systematic reviews that examined the product's effect on symptoms associated with the condition. These trials were conducted during periods of increased symptom activity and studies monitored patient-reported outcomes describing perceived discomfort. The main outcomes examined were related to physical discomfort and acute changes over the course of the menstrual cycle.

The findings describe symptom patterns observed in the studies, particularly during phases of heightened symptom activity. Research highlighted changes measured during the study period in pain intensity scores, and some trials examined the use of concurrent analgesic medication during the study.

What remains uncertain is the full understanding of outcomes beyond the immediate, acute phase. Long-term effects are not fully established regarding the use of Mefenamic Acid over many consecutive cycles. Furthermore, data for certain groups remain insufficient, particularly for women with underlying gynecological conditions or other complex factors.

Evidence for Acute Mild-to-Moderate Pain

The research contributing to the evidence base for acute, mild-to-moderate pain is based on studies exploring short-term symptom changes in various pain models, such as pain following dental procedures or minor surgeries. The research mainly used short-term RCTs with primary outcomes measured over short periods, often just a few hours up to one week.

Long-term Studies and Follow-up Duration

The majority of studies focused on short-term or episodic symptom patterns and did not follow patients for extended periods to observe outcomes reflecting daily functioning or functional ability. The lack of long-term functional data means that research does not determine whether group patterns observed in acute trials can be extrapolated to repeated or prolonged use.

Evidence in Specific Patient Groups

The primary research for Mefenamic Acid studies explored populations that largely included adults and adolescents. Data are still emerging for certain populations, and subgroup findings are uncertain. Evidence for patients in younger age groups or those with complex, pre-existing health conditions is sparse in the controlled trial setting. There is limited information for long-term outcomes in older adults, as they are often excluded from or underrepresented in acute pain trials.

Key Studies & References Mefenamic Acid - LiverTox - Clinical and Research Information on Drug-Induced Liver Injury (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Metaflam (FAQ)

Q: What is the main difference between Metaflam and other common pain relievers?

A: According to official regulatory documents, Metaflam (Mefenamic Acid) is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) that belongs specifically to the fenamate chemical subclass. Other common pain relievers are classified differently; for instance, ibuprofen is a propionic acid derivative, while acetaminophen is a non-opioid analgesic that does not have anti-inflammatory properties. These chemical differences result in distinct pharmacological profiles and use conditions, as described in official documents.

Q: Is Metaflam considered a strong pain medication?

A: Official drug information indicates that this medicine is authorized for the relief of acute mild-to-moderate pain and discomfort. This means its intended use is within the scope of moderate pain relief, as defined by regulatory bodies.

Q: Why does Metaflam have restrictions on who can take it?

A: Restrictions on who can use the medicine are established in official labeling due to the documented risk of serious adverse events. These risks, detailed in official warnings, include cardiovascular events, severe gastrointestinal issues (like bleeding and ulceration), and serious allergic reactions. Regulatory agencies mandate these restrictions to minimize potential harm.

Q: What does 'NSAID' mean in relation to Metaflam?

A: The term 'NSAID' is the abbreviation for Nonsteroidal Anti-inflammatory Drug. Official documents assign Mefenamic Acid to this pharmacological class. This classification signifies that the medicine is designed to manage symptoms related to pain, fever, and inflammation.

Q: Can people with high blood pressure use Metaflam?

A: Official drug documents note that Mefenamic Acid may reduce the blood pressure-lowering effect of certain antihypertensive medicines, such as ACE Inhibitors and Diuretics. Additionally, the medicine is strictly contraindicated for use in patients with severe heart failure.

Q: What official body oversees the safety classification of Metaflam?

A: The safety classification, use protocols, and approved labeling are overseen by various government regulatory agencies globally. These authorities include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which publishes the Summary of Product Characteristics (SmPC).

Q: Why is Metaflam classified as a prescription-only medicine?

A: Mefenamic Acid is designated as prescription-only due to its pharmacological profile and the necessity of patient monitoring. Official warnings describe potential serious safety risks, such as cardiovascular and gastrointestinal events, which require a healthcare provider's oversight.

Q: Is it acceptable to take Metaflam if I have mild indigestion?

A: Indigestion (dyspepsia) is commonly reported as an adverse reaction in clinical studies. Official administration instructions indicate the medicine is taken with food or milk to help lessen potential stomach upset. However, the medicine is strictly contraindicated for individuals who have active gastrointestinal ulceration.

Q: Is Metaflam the same thing as meloxicam?

A: No, official regulatory documents confirm that these are different medicines. The active ingredient in Metaflam is Mefenamic Acid, classified as a fenamate NSAID. Meloxicam is a separate chemical entity that belongs to a different NSAID subclass (an oxicam derivative).

Q: Does Metaflam start working immediately after taking it?

A: Official labeling does not use the term 'immediately' to describe the onset of relief. However, official prescribing information does describe the time it takes for the drug's concentration to reach its maximum level in the bloodstream. This pharmacokinetic data describes the time frame in which the medicine reaches its peak concentration.

Q: How long does the effect of Metaflam usually last?

A: The official dosing schedule for this medicine is established in the regulatory documents with a defined frequency (q6h) for its labeled uses. This frequency is determined based on the drug's half-life, which is the time required for the amount of medicine in the body to be reduced by half.

Q: Why is Metaflam sometimes prescribed once a day?

A: Official administration instructions for the labeled uses (acute pain and primary dysmenorrhea) detail a frequency that is not once daily. The official prescribing information does not describe a once-daily regimen for this medicine.

Q: What evidence exists about Metaflam's use for joint pain?

A: Research overviews describe studies that contributed to the evidence base for acute mild-to-moderate pain and primary dysmenorrhea. These studies do not explicitly name common chronic conditions like specific types of joint pain as authorized indications.

Q: Can Metaflam affect my sleep patterns?

A: Changes to sleep patterns are not explicitly listed in common adverse reactions. However, the labeling does report other central nervous system (CNS) adverse reactions, such as headache and dizziness.

Q: Do doctors often prescribe Metaflam for back pain?

A: The official labeled indication for the medicine is for the relief of acute mild-to-moderate pain. This indication includes pain associated with musculoskeletal injuries, which is the category for most common back pain concerns.

Q: Is it possible to become dependent on Metaflam?

A: Official documents classify Mefenamic Acid as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not categorized as a scheduled controlled substance, which is the classification applied by regulatory agencies to medicines associated with potential dependence or abuse.

Q: Does taking Metaflam require regular blood tests?

A: The official documents describe potential serious risks, particularly when the medicine is used for extended periods. While the drug is only approved for short-term use, the official prescribing information addresses the concept of monitoring steps, which is information available for a healthcare provider's review.

Q: What are the official recommendations on driving while taking Metaflam?

A: Official labeling reports adverse reactions such as dizziness and headache. Official warnings describe that caution is advised regarding driving or operating machinery if the patient experiences any effects that could impair their ability.

Q: Is there a link between Metaflam and fluid retention?

A: Official labeling notes that NSAIDs, including Mefenamic Acid, may cause fluid retention and swelling, known as edema. Furthermore, the medicine is contraindicated in patients with severe heart failure.

Q: Does Metaflam affect the way my body handles salt and water?

A: Official warnings and precautions state that NSAIDs can interfere with the body's fluid balance due to documented effects on the kidneys. These effects may also cause a new onset or worsening of existing hypertension (high blood pressure).

How should Metaflam be stored and disposed of?

How to Store and Dispose of Metaflam?

The storage and disposal of Metaflam (Mefenamic Acid) oral capsules/tablets must comply strictly with official regulatory requirements to ensure product stability and safety.

Storage Conditions

Requirement	Official Regulatory Mandate
Temperature	Must be stored at Controlled Room Temperature (20 C to 25 C).
Protection	Keep in the original container, tightly closed, and protect from excessive heat, light, and moisture.
Safety	Store strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Metaflam should be disposed of via an authorized drug take-back program or mail-back service. If these options are unavailable, the medicine can be mixed with an unappealing substance, sealed in a bag, and discarded in the household trash. The product must not be flushed down the toilet or poured into a drain.

Metaflam